New criteria set for unstable supply and demand drugs
By Lee, Tak-Sun | translator Alice Kang
25.01.13 05:45:42
가나다라
0
Will also evaluate applications for price increases of national essential drugs that use homegrown ingredients
Head of the drug post-management department will attend the Cancer Disease Deliberation Committee meeting…for preemptive response
The Health Insurance Review and Assessment Service has decided to clarify the criteria for evaluating adjustment applications for drugs with unstable supply and demand and strengthen preliminary management of high-priced anticancer drugs.
HIRA announced so on the 9th while issuing a prenotification of the “Partial Amendments to the Evaluation Criteria and Procedures for Whether a Drug is Eligible for Medical Benefits” and the “Partial Amendments to the Operating Regulations of the Severe Disease Deliberation Committee.” The deadline for submitting opinions on the criteria is the 15th.
First, in the prenotification of the “Partial Amendments to the Evaluation Criteria and Pro
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)